Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry P King

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
Contribution of CYP2C9 to variability in vitamin K antagonist metabolismAnn K Daly, Barry P King
Pharmacogenetics|May 2, 2003
Pharmacogenetics of oral anticoagulantsAnn K Daly, Barry P King
Methods in Molecular Biology (Clifton, N.J.)|May 25, 2006
Genotyping for cytochrome P450 polymorphismsAnn K Daly, Barry P King, Julian B S Leathart
Pharmacogenetics|December 21, 2004
Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolismBarry P King, Tayyaba I Khan, Guruprasad P Aithal, et al.
British Journal of Clinical Pharmacology|June 20, 2003
CYP3A5 phenotype-genotype correlations in a British populationBarry P King, Julian B S Leathart, Elaine Mutch, et al.
Clinical Pharmacology and Therapeutics|March 6, 2004
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarinFarhad Kamali, Tayyaba Irfan Khan, Barry P King, et al.
Blood|June 11, 2005
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimenElizabeth A Sconce, Tayyaba I Khan, Hilary A Wynne, et al.
BMC Cancer|August 7, 2009
A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver diseaseJoe Gray, Dipankar Chattopadhyay, Gary S Beale, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Expert Opinion on Drug Metabolism & Toxicology|July 26, 2006
Contribution of CYP2C9 to variability in vitamin K antagonist metabolismAnn K Daly, Barry P King
Pharmacogenetics|May 2, 2003
Pharmacogenetics of oral anticoagulantsAnn K Daly, Barry P King
Methods in Molecular Biology (Clifton, N.J.)|May 25, 2006
Genotyping for cytochrome P450 polymorphismsAnn K Daly, Barry P King, Julian B S Leathart
Pharmacogenetics|December 21, 2004
Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolismBarry P King, Tayyaba I Khan, Guruprasad P Aithal, et al.
British Journal of Clinical Pharmacology|June 20, 2003
CYP3A5 phenotype-genotype correlations in a British populationBarry P King, Julian B S Leathart, Elaine Mutch, et al.
Clinical Pharmacology and Therapeutics|March 6, 2004
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarinFarhad Kamali, Tayyaba Irfan Khan, Barry P King, et al.
Blood|June 11, 2005
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimenElizabeth A Sconce, Tayyaba I Khan, Hilary A Wynne, et al.
BMC Cancer|August 7, 2009
A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver diseaseJoe Gray, Dipankar Chattopadhyay, Gary S Beale, et al.
Pageof 1